118 related articles for article (PubMed ID: 38251775)
1. Risk factors for early recurrence after radical gastrectomy followed by adjuvant chemotherapy for stage II or III gastric cancer: a multicenter, retrospective study.
Yagi S; Kumagai K; Nunobe S; Ishizuka N; Yamaguchi T; Imai Y; Tsuda M; Haruta S; Fukunaga H; Yamada T; Goto M
Jpn J Clin Oncol; 2024 Apr; 54(4):403-415. PubMed ID: 38251775
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea.
Jo JC; Baek JH; Koh SJ; Kim H; Min YJ; Lee BU; Kim BG; Jeong ID; Cho HR; Kim GY
Asia Pac J Clin Oncol; 2015 Dec; 11(4):282-7. PubMed ID: 25856172
[TBL] [Abstract][Full Text] [Related]
4. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
[TBL] [Abstract][Full Text] [Related]
5. [Impact of preoperative lymphocyte to monocyte ratio on the prognosis of the elderly patients with stage II(-III( gastric cancer].
Cong X; Li S; Xue Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Oct; 19(10):1144-1148. PubMed ID: 27781252
[TBL] [Abstract][Full Text] [Related]
6. The predictive factors of gastric cancer recurrence after the completion of adjuvant chemotherapy in advanced gastric cancer.
Kim YJ; Chung WC; Youn GJ; Jun KH; Chin HM
Rev Esp Enferm Dig; 2019 Jul; 111(7):537-542. PubMed ID: 31215209
[TBL] [Abstract][Full Text] [Related]
7. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
[TBL] [Abstract][Full Text] [Related]
8. Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study.
Mitani S; Kadowaki S; Hasegawa H; Wakatsuki T; Hara H; Tajika M; Nishikawa K; Hirao M; Takahari D; Chin K; Muro K
Int J Clin Oncol; 2019 Oct; 24(10):1197-1203. PubMed ID: 31152323
[TBL] [Abstract][Full Text] [Related]
9. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
[TBL] [Abstract][Full Text] [Related]
10. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
11. Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer.
Nishibeppu K; Komatsu S; Ichikawa D; Imamura T; Kosuga T; Okamoto K; Konishi H; Shiozaki A; Fujiwara H; Otsuji E
BMC Cancer; 2018 Jan; 18(1):108. PubMed ID: 29382310
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
[TBL] [Abstract][Full Text] [Related]
13. Different risk factors for three major recurrence patterns of pathological stage II or III gastric cancer patients who completed adjuvant S-1 monotherapy.
Kano Y; Ohashi M; Muneoka Y; Takahari D; Chin K; Yamaguchi K; Ida S; Kumagai K; Makuuchi R; Sano T; Nunobe S
Eur J Surg Oncol; 2021 Dec; 47(12):3097-3104. PubMed ID: 33931261
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.
Yamashita K; Kurokawa Y; Yamamoto K; Hirota M; Kawabata R; Mikami J; Masuzawa T; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2017 Sep; 24(9):2639-2645. PubMed ID: 28608116
[TBL] [Abstract][Full Text] [Related]
15. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
Peng L; Yang W; Zhang Z; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
[TBL] [Abstract][Full Text] [Related]
16. Real-World Therapeutic Outcomes of S-1 Adjuvant Chemotherapy for pStage II/III Gastric Cancer in the Elderly.
Kunisaki C; Sato S; Tsuchiya N; Kubo H; Watanabe J; Sato T; Takeda K; Tamura Y; Kasahara K; Kosaka T; Akiyama H; Endo I
Eur Surg Res; 2021; 62(1):40-52. PubMed ID: 33794520
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with early recurrence after curative surgery for gastric cancer.
Kang WM; Meng QB; Yu JC; Ma ZQ; Li ZT
World J Gastroenterol; 2015 May; 21(19):5934-40. PubMed ID: 26019458
[TBL] [Abstract][Full Text] [Related]
18. Predictors and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer.
Karagkounis G; Squires MH; Melis M; Poultsides GA; Worhunsky D; Jin LX; Fields RC; Spolverato G; Pawlik TM; Votanopoulos KI; Levine EA; Schmidt C; Bloomston M; Cho CS; Weber S; Masi A; Berman R; Pachter HL; Staley CA; Newman E; Maithel SK; Hatzaras I
J Gastrointest Surg; 2017 Dec; 21(12):1984-1992. PubMed ID: 28963709
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a prognostic nomogram for predicting early recurrence after curative resection of stage II/III gastric cancer.
Ma M; Xiao H; Li L; Yin X; Zhou H; Quan H; Ouyang Y; Huang G; Li X; Xiao H
World J Surg Oncol; 2019 Dec; 17(1):223. PubMed ID: 31856828
[TBL] [Abstract][Full Text] [Related]
20. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2011 Aug; 14(3):274-8. PubMed ID: 21461654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
